Related Experiment Video
Updated: Feb 19, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
Curtis Triplitt1, Debbie Hinnen2, Virginia Valentine3
1Texas Diabetes Institute, University Health System, University of Texas Health Science Center, San Antonio, TX.
Abstract:
IN BRIEF As more patents on biological medicines expire, increased numbers of biologic copies, referred to as "biosimilars," will likely become available in the United States in the coming years. With greater availability and the drive for health care savings, the use of biosimilars and of "follow-on" biological products is likely to increase in routine clinical practice. Health care practitioners need to be fully aware of these products and accompanying considerations if they are to make informed decisions together with their patients.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence: Overview
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Bioequivalence of Drugs: Drugs with Multiple Indications
Pharmaceutical Equivalents
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...

